The standard measure of lesion count may matter less than the underlying biology driving treatment response in ...

Revvity targets 2026 growth with multiomics, AI-powered base editing, NGS newborn screening, and immunotherapy advances.

With the MiSeq™ i100 Series, Illumina continues to set the highest standards.Advancements in system design, sequencing chemistry, and data analysis deliverthe simplest, fastest benchtop sequencing and ...

Spatial RNA medicine combines transcriptomics and RNA therapeutics, mapping gene expression in tissues to enhance precision ...

Antibody Specificity Testing Market is expected to Reach to US $1.9 Bn by 2035, Driven by Rising Demand for Personalized ...